(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 June 2021 (24.06.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/127231 A1

(51) International Patent Classification:
A61P 37/00 (2006.01) *A61K 31/519* (2006.01)
C07D 487/04 (2006.01)

(21) International Application Number:
PCT/US2020/065689

(22) International Filing Date:
17 December 2020 (17.12.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/951,958 20 December 2019 (20.12.2019) US
63/122,309 07 December 2020 (07.12.2020) US

(71) Applicant: **PRINCIPIA BIOPHARMA INC.** [US/US]; 220 East Grand Avenue, South San Francisco, California 94080 (US).

(72) Inventors: **PHIASIVONGSA, Pasit**; c/o Principia Biopharma Inc., 220 East Grand Avenue, South San Francisco, California 94080 (US). **CHU, Katherine**; c/o Principia Biopharma Inc., 220 East Grand Avenue, South San Francisco, California 94080 (US). **ZHU, Jiang**; c/o Principia Biopharma Inc., 220 East Grand Avenue, South San Francisco, California 94080 (US). **BY, Kolbot**; c/o Principia Biopharma Inc., 220 East Grand Avenue, South San Francisco, California 94080 (US). **MASJEDIZADEH, Mohammad**; c/o Principia Biopharma Inc., 220 East Grand Avenue, South San Francisco, California 94080 (US).


(74) Agent: **MADL, Amy C.** et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, District of Columbia 20001-4413 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: SOLID FORMS OF 2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE



(I)

(57) Abstract: Solid forms of Compound (I): are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions mediated by BTK activity using the same, and methods for making Compound (I) and solid forms thereof are also disclosed.

WO 2021/127231 A1